CareDx De-risks with Overturned Patent Verdict, Closed DOJ/SEC Probes, and Remedied Internal Controls
CDNA sits 68% above its 52-week low of $10.96 on elevated volume (2.0× avg).
Summary
CareDx reported strong full-year 2025 revenue growth and significant legal victories, including the overturning of a $96.3 million patent verdict and the closure of DOJ/SEC investigations without enforcement. The company also successfully remediated a material weakness in internal controls and completed $87.8 million in share repurchases.
Key Events · Corporate Governance and Compliance · CDNA
-
Major Patent Verdict Overturned
The U.S. Court of Appeals for the Third Circuit affirmed the District Court's decision to overturn a $96.3 million jury verdict against CareDx, finding Natera's asserted patents invalid. This removes a significant financial liability.
-
DOJ and SEC Investigations Concluded
The Department of Justice declined to intervene in a qui tam action, effectively closing its investigation with no finding of wrongdoing. The SEC also concluded its investigation into similar matters without recommending enforcement action, removing substantial regulatory uncertainty.
-
Material Weakness in Internal Controls Remedied
CareDx successfully remediated a previously disclosed material weakness in its internal control over financial reporting as of December 31, 2025, enhancing the reliability of its financial statements.
-
Significant Share Repurchases
The company completed $87.8 million in share repurchases during 2025 under its February and May 2025 programs, demonstrating a commitment to returning capital to shareholders.
Analysis · CDNA · Industrial Applications And Services
This annual report reveals significant positive developments that substantially de-risk CareDx and improve its operational and legal standing. The overturning of a $96.3 million patent infringement verdict against Natera, coupled with the closure of both DOJ and SEC investigations without enforcement action, removes major financial and regulatory overhangs that have weighed on the company. Furthermore, the successful remediation of a previously disclosed material weakness in internal controls over financial reporting enhances investor confidence in the company's financial integrity. While the company reported a net loss for 2025, the strong revenue growth and substantial share repurchases demonstrate operational progress and a commitment to shareholder returns. These combined factors present a significantly improved outlook for CareDx.
At the time of this filing, CDNA was trading at $18.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $949.4M. The 52-week trading range was $10.96 to $22.95. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.